16 active not recruiting, 7 recruiting, 3 completed, 3 withdrawn. 33 Phase 2, 9 Phase 1, 1 Phase 3.
Follow X-Ray Imaging: new trials by email Literature Review of X-Ray Imaging trials Research Report on X-Ray Imaging
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma | Phase 2 | Not yet recruiting | Northwestern University | 56 | 2027-05-05 | 2026-10-07 |
| Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Neuroblastoma | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | 77 | 2027-04-09 | 2026-09-15 |
| Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Cytokine Release Syndrome, Recurrent Multiple Myeloma | Phase 2 | Recruiting | Naresh Bumma | 35 | 2026-07-17 | 2026-10-06 |
| Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial Allogeneic Hematopoietic Stem Cell Transplantation, Axatilimab, Biospecimen Collection - Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Withdrawn | Mayo Clinic | 2026-06-01 | 2026-09-03 | |
| ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Suspended | Fred Hutchinson Cancer Center | 33 | 2025-12-27 | 2026-09-11 |
| CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Mismatch Repair Proficient Colorectal Carcinoma, Refractory Mismatch Repair Proficient Colorectal Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2025-09-11 | 2026-11-03 |
| XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Locally Advanced Differentiated Thyroid Gland Carcinoma, Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma | Phase 2 | Recruiting | Jochen Lorch | 33 | 2025-06-06 | 2026-06-26 |
| Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy Interferon Beta-1A, X-Ray Imaging, Echocardiography - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2025-04-01 | 2024-07-12 | |
| Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2024-08-09 | 2024-05-17 | |
| A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) Biopsy Procedure, Biospecimen Collection, Chest Radiography - Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 50 | 2024-06-25 | 2026-10-14 |
| Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy Bupivacaine, Hydromorphone, Iopamidol - Duodenal Neoplasm, Pancreatic Neoplasm | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 78 | 2023-11-10 | 2026-02-03 |
| Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial Bone Marrow Aspiration, Daratumumab, Echocardiography Test - AL Amyloidosis | Phase 2 | Recruiting | Mayo Clinic | 96 | 2023-09-06 | 2026-10-01 |
| FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer Balstilimab, Bevacizumab, Biospecimen Collection - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 20 | 2023-05-03 | 2026-09-01 |
| A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma Bone Scan, Cabozantinib S-malate, Cisplatin - High Grade Osteosarcoma, Localized Osteosarcoma | Phase 2 / Phase 3 | Suspended | National Cancer Institute (NCI) | 1122 | 2023-03-03 | 2026-10-27 |
| Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors Atezolizumab, Biospecimen Collection, Computed Tomography - Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 86 | 2022-11-17 | 2026-07-14 |
| Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904) Treosulfan, Fludarabine Phosphate, Tacrolimus - Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 40 | 2022-04-19 | 2026-03-09 |
| Pomalidomide Treatment in Patients With Kaposi Sarcoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Skin Kaposi Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 45 | 2022-03-18 | 2026-09-28 |
| Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy Anakinra, X-Ray Imaging, Positron Emission Tomography - B-Cell Non-Hodgkin Lymphoma | Phase 2 | Completed | Fred Hutchinson Cancer Center | 27 | 2021-12-27 | 2025-10-23 |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint - Colorectal Carcinoma, Endometrial Carcinoma | Phase 1 / Phase 2 | Recruiting | Children's Oncology Group | 147 | 2021-11-08 | 2026-08-25 |
| Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial Carfilzomib, Dexamethasone, Pomalidomide - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 39 | 2021-05-06 | 2026-02-25 |
Showing 20 of 33. Sign in to see all of them.
Wilms Tumor (8) · Hepatoblastoma (7) · Lymphoma, Non-Hodgkin (7) · Neuroblastoma (7) · Osteosarcoma (7) · Rhabdoid Tumor (7) · Ependymoma (6) · Glioma (6) · Histiocytosis, Langerhans-Cell (6) · Medulloblastoma (6) · Neuroectodermal Tumors, Primitive, Peripheral (6) · Sarcoma (6) · Central Nervous System Neoplasms (5) · Rhabdomyosarcoma (5) · Sarcoma, Ewing (4)
National Cancer Institute (NCI) (17) · Children's Oncology Group (4) · Fred Hutchinson Cancer Center (4) · Mayo Clinic (3) · City of Hope Medical Center (1) · Jochen Lorch (1) · Masonic Cancer Center, University of Minnesota (1) · Naresh Bumma (1) · Northwestern University (1)
United States (31) · Canada (9) · Puerto Rico (9) · Australia (8) · New Zealand (4) · Saudi Arabia (1)
Jordan Gauthier (2) · Alexandre V. Hirayama, MD (1) · Alice Lee (1) · Amit J Sabnis (1) · Andrea T Franson (1) · Anjali S Advani (1) · Chaoyuan Kuang (1) · Donald W Parsons (1) · Dwight H Owen (1) · Emily K Bergsland (1) · Fariba Navid (1) · James Flaherty (1) · James I Geller (1) · Jochen H Lorch (1) · Jochen H Lorch, MD (1)
PMID 31401903, PMID 33591402, PMID 34486544, PMID 35353553, PMID 36322825, PMID 40902132, PMID 41166674, PMID 42686334, PMID 42867148
U10CA180886 (10), UM1CA228823 (3), P30CA060553 (2), U10CA180888 (2), UM1CA186688 (2), P30CA033572 (1), P30CA077598 (1), R21CA288898 (1), U10CA031946 (1), U10CA180821 (1), U10CA180830 (1), U10HL069294 (1), UM1CA081457 (1), UM1CA121947 (1), UM1CA186644 (1)